Stay current with MiRXES


Media Releases

Keep up to date with our latest news and activities as we continue to innovate and develop our science and technology, bringing novel products to market – from Singapore to the World.

29 November 2022

MiRXES signed a Memorandum of Understanding with PT ELION MEDIKA INDONESIA (PT ELION) to validate and commercialize MiRXES’s microRNA cancer blood tests for stomach and lung cancers in Indonesia, and establish CADENCE-ID, a joint project for the optimization and validation of a novel multi-cancer blood test, based on blood-borne circulating miRNA and DNA methylation biomarkers in the Indonesian population, for up to nine high incidence and high mortality cancers.

22 November 2022

MiRXES together with Guest of Honor Dr. Wang Jian, Co-founder and Chairman of BGI Group, unveiled today the cutting-edge DNBSEQ-T10×4RS Genetic Sequencing System (T10), the world’s largest and highest throughput next generation sequencer. The T10 sequencing platform will provide a significant boost to Singapore’s sequencing power and build a high-resolution spatial transcriptomics pipeline in Singapore.

25 October 2022

MiRXES today launches the first edition of MiRXES Translator Program, Southeast Asia’s first business and clinical advisory program backed by science that bridges post-incubation ideation and post-accelerator growth, at Singapore Week of Innovation and Technology (SWITCH). This program will accelerate revenue growth of start-ups and importantly, adoption of preventive healthcare solutions globally.

22 September 2022

Singapore-headquartered biotech MiRXES, National University Heart Centre, Singapore (NUHCS) and National Heart Centre Singapore (NHCS) launch SPHERE (Singapore Pulmonary Hypertension Early detection with miRNA biomarkErs) study to identify biomarkers that are relevant to early detection of pulmonary hypertension with the aim to improve Asian patient outcomes and save lives.

18 September 2022

MiRXES announced today the donation of SG$88,902 to the National University Cancer Institute, Singapore (NCIS) Cancer Fund, a sub-fund of NUHS Fund, at the closing ceremony of Let’s Ride! Singapore today, to assist less fortunate cancer patients with critical cancer treatments. This event was graced by Guest-of-Honor, Ms. Low Yen Ling, Minister of State, Ministry of Trade and Industry & Ministry of Culture, Community and Youth, and Mayor of South West District, who witnessed the cheque presentation ceremony.

7 July 2022

MiRXES announced announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd) and also officially opened its R&D and clinical diagnostic labs in Biopolis, Singapore.

7 June 2022

MiRXES has formed a strategic partnership with BGI-Research, an internationally renowned genomics research institution, and MGI, a leading developer and provider of high-throughput sequencing platforms, to accelerate spatio-temporal transcriptomics and multi-omics research in human development and diseases.

27 May 2022

MiRXES announced today the opening of the first industry 4.0 (i4.0) in vitro diagnostic (IVD) manufacturing facility in Southeast Asia. This S$8 million facility at JTC MedTech Hub is the largest i4.0 IVD manufacturing site at in Southeast Asia at 15,000 square feet. Guest-of-Honour, Mr Gan Kim Yong, Minister for Trade and Industry, graced the opening ceremony.

12 April 2022

MiRXES announced today the appointment of Professor Tony Mok, a world-renowned medical oncologist, to its Scientific Advisory Board (SAB). Professor Mok co-founded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group and has led multiple multi-national studies that help establish the global standard on personalized medicine for lung cancer.

15 February 2022

MiRXES announced today the set-up of its Hong Kong office and the appointment of Mr. Martin LAW as Managing Director in Hong Kong, who will report to MiRXES’s Co-founder and CEO, Dr. Lihan ZHOU. Mr. Law will lead the establishment and operations of MiRXES Hong Kong Limited, to explore partnerships in providing accurate, affordable and accessible cancer early detection to the Hong Kong and Greater Bay Area communities.

22 November 2021

MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.

Media Coverage

Stay informed and keep abreast with our media news.

26 Jan 2023

The Straits Times – Netball Singapore (NS) has received a boost ahead of a busy year for the national team, with local biotechnology company MiRXES coming on board as title sponsor of the 2023 and 2024 Nations Cup.

20 Apr 2022

HKET – 疫情加速了科技融入医药学科研范畴,生物科技行业开始获得市场关注。专注于核糖核酸(RNA)科技的新加坡高生物科技企业「觅瑞」(MiRXES),自2014年起致力于研发疾病早诊技术与将其商业化。现时业务遍布香港、中国、日本、美国等45个国家及地区,故吸纳人才成为其首要挑战。 该企藉创造一个较人性化及较灵活的工作环境等3招,以招徕人才。


Our partnerships

15 Sep 2021

ヒューマン・メタボローム・テクノロジーズ株式会社 代表取締役社長 橋爪 克仁 、 本社 山形県鶴岡市、以下「 HMT 」 と 、 MiRXES (ミレックサス Chief Executive Officer Zhou Lihan 、本社: シンガポール 、以下「 MiRXES 」 は、 マイクロ RNA 関連製品・サービスを日本において展開することに合意し、販売契約を締結しました 。

31 Aug 2021



Welcome to our knowledge base of insights in the frontiers of the biotech industry.

Congratulations to Associate Professor Too Heng-Phon from the Department of Biochemistry and NUS Centre for Cancer Research at NUS Medicine, who has been conferred the President’s Technology Award 2021.

Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats — to great success.

Media Contact

For media enquiries, please email:
Copyright © 2022 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top